Our
Team
Foster Delivery Science has attracted elite strategic and operational talent to help us support the success of our customers.
Meet our Leadership Team below.

Lawrence Acquarulo
President & CEO
Larry founded Foster Corporation in 1989 and has been CEO since inception. In 2005, Larry founded Foster Delivery Science, a division of Foster Corporation dedicated to the processing of high regulated polymers & active ingredients for drug delivery applications. Under his leadership, Foster Corporation and Foster Delivery Science has become a world-wide leader in polymer and process technology for the medical device and pharmaceutical industries.

Anthony Listro
Vice President of Technology
Tony has worked in the polymer industry for more than 25 years in technical management positions, responsible for polymer processing and polymer formulations. Tony has more than 15 years’ experience in the pharmaceutical field, holding two issued U.S. patents and authoring / co-authoring more than fifteen publications. Tony has a BS and MS in Plastics Engineering from the University of Massachusetts in Lowell, MA and an MBA from the Isenberg School of Management at the University of Massachusetts in Amherst, MA.

Breanna Rinaldo
Director of Operations
Breanna is an enthusiastic and experienced Program Manager, with a special niche for medical device and pharmaceutical product manufacturing. She is responsible for the overall success, leadership, and strategic management of Program Operations, including new product development as well as commercial manufacturing. Breanna holds a B.S. in Biology & Biotechnology, a M.S. in Management, and a M.B.A from Worcester Polytechnic Institute.

Robert Sterling
Director of Business Development
Rob offers a wealth of experience in pharmaceutical business leadership and development, previously holding executive level positions with multinational Hoechst-Roussel Pharmaceuticals and public biotech startup Bioenvision. Rob maintains advisor/founder roles with biotech startups to seek funding for conventional and gene therapies aimed at oncology, immunology, and pulmonary diseases. Rob has a B.A. from Penn State University.